REG - Syncona Limited - Directorate Change

SynconaAnnouncement

05/08/2025 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250805:nRSE0848Ua&default-theme=true

RNS Number : 0848U  Syncona Limited  05 August 2025

05 August 2025

Syncona Limited

 

("Syncona" or the "Company")

 

Directorate Change

As previously announced, following Syncona Limited's Annual General Meeting
("AGM"), Virginia Holmes has retired from the Syncona Board. Kemal Malik will
take up the role of Senior Independent Director, effective immediately. He
joined the Syncona Board in 2020, bringing 30 years of experience in global
pharmaceutical research and development.

In line with the Company's strategy update on 19 June, in the event a new
investment objective and policy, is approved by shareholders, the Company
would expect to reduce the size of the Board for the new strategy.

Melanie Gee, Chair of Syncona Limited, said: "The Board and Syncona Investment
Management Limited team would like to thank Virginia for her invaluable
contribution to the Company and dedicated work on behalf of our shareholders.
I am delighted that, having worked closely alongside Kemal over the last five
years, he is taking up the role of Senior Independent Director, bringing his
wealth of expertise to bear, as the SIML team seek to maximise value across
the portfolio."

Enquiries

 

Syncona Ltd

 

Annabel Clark

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

 

Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of investments of
Syncona Limited. These statements and forecasts involve risk and uncertainty
because they relate to events and depend upon circumstances that may or may
not occur in the future. There are a number of factors that could cause actual
results or developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies in the
Syncona Limited portfolio are conducting scientific research and clinical
trials where the outcome is inherently uncertain and there is significant risk
of negative results or adverse events arising. In addition, many companies in
the Syncona Limited portfolio have yet to commercialise a product and their
ability to do so may be affected by operational, commercial and other risks.

 

Syncona Limited seeks to achieve returns over the long term. Investors should
seek to ensure they understand the risks and opportunities of an investment in
Syncona Limited, including the information in our published documentation,
before investing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASSLFDIEISESA